 Shares of Atea Pharmaceuticals Inc. AVIR, -68.50 took a 70.7 nosedive on heavy volume toward a record low in morning trading Tuesday, after the biopharmaceutical company said a Phase 2 trial of its oral treatment of SARS-CoV-2 virus in an outpatient setting failed to meet its primary endpoint. Trading volume swelled to 21.6 million shares, compared with the full-day average of about 2.7 million shares. 